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A B S T R A C T
Women living with HIV in Africa are at increased risk to be co-infected with Human Papilloma Virus (HPV),
persistent high risk (HR) HPV infection and bacterial vaginosis (BV), which compounds HPV persistence, thereby
increasing the risk for cervical dysplasia. New guidance from WHO in 2014 advocating for a “screen and treat”
approach in resource poor settings is becoming a more widely recommended screening tool for cervical cancer
prevention programs in such contexts. This review article summarizes the risk factors to be considered when
designing a primary and secondary cervical prevention program in a post-vaccination era for HIV-infected
women in Kenya.
This review article is based on our prior research on the epidemiology of pHR/HR-HPV genotypes in HIV-
infected women and CIN 2+ in Kenya and other sub-Saharan contexts. In order to contextualize the ﬁndings, a
literature search was carried out in March 2017 by means of four electronic databases: PUBMED, EMBASE,
SCOPUS, and PROQUEST.
Risk factors for potential (pHR)/HR HPV acquisition, including CD4 count, HAART initiation, Female Sex
Worker status (FSW) and BV need to be considered. Furthermore, there may be risk factors for abnormal cy-
tology, including FSW status, multiple potential (p)HR/HR HPV genotypes, which may require that HIV-infected
women be subjected to screening at more frequent intervals than the three year recommended by the WHO. The
quadruple synergistic interaction between HIV, HPV and BV and its related cervicitis may need to be reﬂected
within a larger prevention framework at the community level. The opportunities brought forth by the roll out of
HAART could lead to task shifting of HIV-HPV-BV care to nurses, which may increase access in poorly-served
areas.
1. Background
Kenya is home to the world's fourth-largest HIV epidemic. In 2013,
an estimated 1.6 million people were living with HIV and roughly
57,000 people died from AIDS-related illnesses (UNAIDS, 2013). In
2007, the World Health Organization (WHO) included Invasive Cervical
Cancer (ICC) to stage “4” of the HIV/AIDS clinical classiﬁcation of
staging for resource-constrained settings (WHO Department of
Immunization, Vaccines and Biologicals, World Health Organization;
Geneva, 2007).
More than 200 types of human papillomaviruses (HPV) have been
identiﬁed, of which 40 can progress to high-grade precancerous squa-
mous intraepithelial lesions (HSILs) and subsequent invasive cervical
cancer (ICC) (de Villiers et al., 2004). Although most HPV infections
clear without intervention within 1 year, certain High Risk HPV (HR-
HPV) genotypes have a propensity to persist and are consequently the
chief risk factor for the development of ICC (Koshiol et al., 2008). The
15 HR oncogenic viral strains, which have been identiﬁed, can be
broken down into diﬀerent species: the HPV 16 group (alpha-9) of the
alpha-papillomavirus genus (HPV 31, 33, 35, 52, and 58), the HPV 18
group (alpha-7; HPV 39, 45, 59, and 68) and the alpha-6, genotype HPV
56 (Li et al., 2011; Rodríguez-Cerdeira et al., 2009).
Sexually transmitted infections (STIs) have been associated with
longer HR-HPV persistence in previous studies (King et al., 2011). The
prevalence of Bacterial Vaginosis (BV) in African women, characterised
by an overgrowth of vaginal anaerobic ﬂora and reduction of H2O2-
http://dx.doi.org/10.1016/j.gore.2017.10.002
Received 3 August 2017; Received in revised form 6 October 2017; Accepted 14 October 2017
⁎ Corresponding author at: International Centre for Reproductive Health (ICRH), Ghent University, De Pintelaan 185 P3, 9000 Ghent, Belgium.
E-mail addresses: sonia.menon@ugent.be (S. Menon), steven.callens@ugent.be (S. Callens).
Gynecologic Oncology Reports 22 (2017) 82–88
Available online 16 October 2017
2352-5789/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
producing lactobacilli, is among the highest worldwide (Morris et al.,
2001). The high BV prevalence is of particular concern as there is
evidence that BV is a risk factor for acquisition and transmission of
many STI's, including HIV and HPV (Cohen et al., 2012; Martin et al.,
1999). A meta-analysis also suggested a positive association between
BV and cervical pre-cancerous lesions (Gillet et al., 2012a). Cervical
inﬂammation has been associated with cervical intraepithelial neo-
plasia (CIN) and may be a cofactor for high-grade cervical lesions in
HPV-infected women (Castle et al., 2001a). BV frequently coexists with
cervicitis (Sweet, 2000a) and was found to be an independent risk
factor for cervicitis (Marrazzo, 2006; Platz-Christensen et al., 1994;
Sweet, 2000b), which may be a risk factor for cervical dysplasia in its
own right (Castle et al., 2001b; Liu et al., 2016).
The WHO recommends the inclusion of HPV vaccination in national
immunization programs as HPV represents a public health priority, and
vaccine delivery is feasible and cost-eﬀective (World Health
Organization (WHO), 2014a). Whilst immunogenicity trials have shown
the eﬀectiveness of a two-dose HPV vaccine against HPV 16 and HPV
18 in HPV-naive girls aged 9–14 (Markowitz, 2016), the WHO still
recommends that immunocompromised/HIV-infected girls aged 9–14
be administered a third dose (World Health Organization, 2017a).
However, this will not obviate the need for secondary prevention in
Kenya, where our recent meta-analysis (2016) on the distribution of
pHR/HR HPV genotypes in HIV-infected women in Kenya found a
pooled estimated prevalence of HPV 16 and 18 of 61% in HIV-infected
women with ICC (Menon et al., 2016a). This ﬁnding underscores a need
for a broader primary prevention program than the quadrivalent vac-
cine (Gardasil™) that protects against HPV genotypes 6, 11, 16 and 18
that is currently being rolled out (Garland & Smith, 2010). In addition,
in light of the limited vaccine uptake in Kenya (Vermandere et al.,
2015) in tandem with poor cervical cytology infrastructure, Kenyan
women with undiagnosed or untreated severe cervical lesions may be at
high risk of developing ICC (Crum et al., 2003).
The more feasible, and WHO-approved, strategy for cervical cancer
screening in low resource settings, like Kenya is visual inspection with
acetic acid (VIA) or visual inspection with Lugol's iodine (VILI), al-
though cytological screening is available in Kenyan urban settings.
Women with HIV infection are recommended by the Centers of Disease
Control (CDC) to have more frequent screening with cervical cytology:
twice in the ﬁrst year after diagnosis of HIV and, if normal, annually
thereafter (CDC, 2010). However, the WHO recommends that women
living with HIV be screened within 3 years if tested negative by VIA or
cytology (World Health Organization (WHO), 2014b).
The regular immunological and/or virological followup that ac-
companies the latest WHO recommendation to initiate HAART re-
gardless of the CD4 count provides a golden opportunity to increase
cervical screening. However it is expected that Kenya will need to
utilize more public health resources to expand laboratory facilities to
monitor HIV viral load and, by default, CD4 count to monitor treatment
eﬃcacy (Menon, 2010). As a corollary, this may leave even fewer re-
sources for cervical cancer preventive measures while HIV-infected
women will live longer, thereby potentially experiencing an increased
incidence of ICC. This review ﬁrstly discusses clinical, virological and
behavioural risk factors for pHR/HR-HPV genotypes to take into con-
sideration when designing a triage-based cervical cancer prevention
programme; secondly, it discusses programmatic issues related to im-
plementation.
2. Methodology
We contextualized our prior research on Kenya and on the sub
Saharan African continent, consisting of systematic reviews, meta
analyses, and cross sectional studies, by carrying out a literature search
in April 2017 by means of four electronic databases: PUBMED,
EMBASE, SCOPUS, and PROQUEST.
2.1. Association between BV and cervical pre-cancerous lesions in Africa
Relevant studies on the association between BV and cervical pre-
cancerous lesions were identiﬁed through an extensive search of the
electronic databases based on the following key words: ‘bacterial va-
ginosis’, ‘bacterial infections and vaginitis’ in combination with ‘cer-
vical intraepithelial neoplasia’ (CIN), ‘squamous intraepithelial lesions’
(SIL), ‘cervical lesions’, ‘cervical dysplasia’, and ‘cervical screening AND
Africa’.
2.2. Distribution of HPV genotypes in HIV-infected women in Kenya
The domains of the search terms were HIV, HPV, cervical cancer,
incidence or prevalence, and Kenya. We combined HPV and cervical
cancer with the Boolean operator “OR”, and the result was combined
with the other terms with “AND”.
2.3. Association between BV and alpha 9 related HPV genotypes
‘Bacterial vaginosis’, ‘bacterial infections and vaginitis’ in combi-
nation with alpha 9 related HPV genotypes.
2.4. Association between vaginal inﬂammation and VIA speciﬁcity
‘Vaginal inﬂammation’ AND VIA OR visual inspection with acetic
acid AND speciﬁcity.
2.5. Task shifting of cervical cancer prevention in Africa
Task shifting AND cervical cancer screening OR prevention AND
HIV treatment infrastructure AND Africa.
2.6. Treatment of bacterial vaginosis in HIV-infected women
Metronidazole OR treatment AND Bacterial vaginosis OR ‘bacterial
infections and vaginitis’ AND HIV.
2.7. Self-sampling of HPV in Africa
HPV self-test AND sub Saharan Africa.
3. Results
Fifteen studies were included, one of which is still in press.
3.1. Risk factors for HPV acquisition
3.1.1. Triage according to HIV, HAART and CD4 count
Our meta-analysis demonstrated a high burden of HR-HPV geno-
types with 64% (95%CI: 50%–77%) in a general HIV population in
Kenya (Menon et al., 2016a), signiﬁcantly higher than a recent meta-
analysis on pooled HPV prevalence in the general female population in
eastern Africa (42.2%) (Ogembo et al., 2015). This ﬁnding suggests that
a compromised immune system may be a risk factor for HR-HPV ac-
quisition. Our recent systematic review of HAART and its association on
the presence of HPV, pre-malignant and malignant cervical lesions in
Sub-Saharan Africa suggests that there is evidence that duration of
HAART treatment along with the CD4 count may reduce the prevalence
of high–risk HPV (HR-HPV) (Menon et al., 2017a).
However, the immuno-epidemiology of each HPV genotype remains
inadequately elucidated. This can be prone to variations based on the
culturally diﬀerent follow-up algorithms and endpoint evaluations,
quality of cytological specimens and biopsies taken along with het-
erogeneous HPV genotyping methods available (Padalko et al., 2015).
In Kenya, our exploration of the association between diﬀerent levels of
immunosuppression and pHR/HPV genotypes suggests that the (WHO,
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2013) recommendation to initiate HAART regardless of CD4 count may
oﬀer opportunities to prevent HPV 53 and multiple HPV infections, and
thereby reduce the potential for cervical dysplasia in HPV-vaccinated
women (Menon et al., 2016b). However, the signiﬁcant association
between CD4 count≥ 350 μl and HPV 16 we observed suggests that for
HIV positive unvaccinated women, a CD4 based triage may not be as
eﬀective as they may still be at risk for this oncogenic genotype (Menon
et al., 2016b).
3.2. Synergistic interactions
3.2.1. BV-based triage - association between BV and alpha 9 related
genotypes
Our research in the clinical epidemiology of pHR/HR-HPV geno-
types indicates the vulnerability of HIV-infected women with BV. Our
ﬁndings suggest a potential beneﬁcial impact of BV treatment to reduce
the risk of HR-HPV genotype acquisition. In line with a study in Spain
having found BV to be a predictor for alpha 9 related genotypes
(Rodriguez-Cerdeira et al., 2012), we have found BV to be a predictor of
the HPV 16 genetically related HPV 58 in HIV-positive women (Menon,
2010; Menon et al., 2017b). This ﬁnding underscores the need to con-
sider a potential synergistic eﬀect between BV and phylogenetically
related HPV 16 genotypes. It may be hypothesized that treatment of BV
may be an eﬀective intervention to prevent subsequent HPV infection.
3.3. Risk factors for abnormal cytology
3.3.1. A bacterial Vaginosis-based triage
Apart from its beneﬁts for preventing HR-HPV acquisition in HIV-
infected women, a BV based initial triage can be an eﬀective component
of a secondary cervical cancer prevention program. The vaginal in-
ﬂammation caused by BV may result in increasing HIV viral load, which
in turn can lead to enhanced cervical dysplasia progression (Cardillo
et al., 2001). This relation may accentuate the positive association that
a meta-analysis suggested between BV and cervical pre-cancerous le-
sions (pooled OR: 1.51) (Gillet et al., 2012b).
Moreover, in a clinical setting, inﬂammation may result in a false
positive VIA if the appearance of leukocytes in the submucosa mimics
white epithelium (Davis-Dao et al., 2008). A BV-based primary triage
for HR-HPV acquisition in HIV-infected women and treatment thereof
may have the additional beneﬁt of diminishing cervicitis, which studies
have shown its confounding nature on VIA results, resulting in women
with cervicitis being more likely to have false positive VIA results than
women without cervicitis (Davis-Dao et al., 2008; Vedantham et al.,
2010).
Our study on HIV-infected women in Kenya, which found a cervi-
citis prevalence of 15% (Menon et al., 2016b) highlights the impact that
BV-related cervicitis might have on diagnosis by rendering VIA inter-
pretation less speciﬁc. In turn, a VIA based “screen and treat” approach
without histological conﬁrmation may be too sensitive, leading to
overtreatment of women (WHO, 2013). A study of a HIV-infected po-
pulation in Uganda reported that a VIA based “see and treat” strategy
may have resulted in overtreatment by 72% (439 out of 625) (Mutyaba
et al., 2010).
In contrast to the signiﬁcant association (OR 4.0; 95% CI,
1.07–15.1) (Kharsany et al., 1993) observed between BV and abnormal
cytology in HIV-negative women in South Africa, our study did not ﬁnd
a statistically signiﬁcant association between BV and abnormal cy-
tology (Menon et al., 2017b). It may be that the vulnerability of our
FSW clandestine population exposed them to competing risk factors,
which in turn may have diluted the association between BV and ab-
normal cytology. Furthermore, BV in the South African study was di-
agnosed using the Amsel criteria, which had lower sensitivity and
higher speciﬁcity than the Nugent scoring system, the gold standard
(RangariAmit et al., 2013) that we have used.
3.3.2. Triage based on HIV-infected Female Sex Workers (FSW)
In light of the ﬁnancial constraints that preclude universal
screening, as well as the high pooled prevalence of pHR/HR-HPV
genotypes among the HIV-infected population of 64% (95%CI:
50%–77%) (Menon et al., 2016a), enhanced screening may need to be
devised for certain groups.
A borderline statistically signiﬁcant diﬀerence in our recent meta-
analysis in Kenya between pooled estimates of HR-HPV genotypes in
FSW and the general HIV population suggested that a cost-eﬀective
approach for cervical cancer prevention may warrant a triage based on
this risk factor (Menon et al., 2016a). Moreover, our study found that of
the 192 HIV-infected FSW, 27.1% (95% CI: 20.9–34.0%) had abnormal
cytology (Menon et al., 2017b). However, given the penal code speci-
ﬁcally penalising prostitution in Kenya (International Models project on
women's right, 2011), failure to guarantee anonymity of this group may
preclude the implementation of prevention programmes targeting this
population at risk (Musyoki et al., 2015). Also, the non-randomness of
snowball sampling of FSW, which is used in most of the research for this
group, precludes generalizing ﬁndings to the larger FSW population in
Western Kenya, as the sampling strategy may have excluded FSWs
without any social networks.
3.3.3. Immunosuppression
According to our systematic review, in sub Saharan Africa, the CD4
count, rather than HAART coverage or its duration, plays a central role
in the prevalence of CIN 2 and CIN 3, which suggests the importance of
earlier immune reconstitution (Menon et al., 2017a). Therefore, with
CD4 count appearing in the causal pathway between HAART and
CIN2+, HAART may have an indirect eﬀect on decreasing the pre-
valence of CIN2+.
3.3.4. Multiple pHR/HR-HPV genotypes
Our meta-analysis on Kenya found that the prevalence of multiple
pHR/HR-HPV genotypes was very prominent not only in normal to ab-
normal cytology but also in ICC (48%; 95% CI: 37%-60% and 35%; 95% CI
0.25%–45%, respectively) (Menon et al., 2016a). This association suggests
that a triage for further cytological screening based on the presence of
multiple HPV genotypes may be warranted.
3.4. Programmatic issues of preventive programmes
Whilst early diagnosis and treatment of cervical pre-cancerous le-
sions prevent up to 80% of cervical cancers in high resource countries
where cervical cancer screening is routine (Sankaranarayanan et al.,
2001), in sub Saharan African, regular follow up of cervical cytology is
not feasible. A study in Kenya found that a signiﬁcant percentage of
women (56–80.6%) (Maranga et al., 2013) is only identiﬁed once their
cervical cancer is at an advanced stage. Furthermore, a study in Tan-
zania reported that women co-infected with HIV are less likely to be
treated (Mosha et al., 2009).
A roll out of cervical preventive programmes throughout under-
served rural setting Kenya will necessitate a change in the cervical
cancer prevention landscape. Such a programme should be designed
considering the limited resources. Indeed, a recent survey among health
care workers found that the main barriers to service provision were
staﬃng shortages and insuﬃcient staﬀ training (Rosser et al., 2015).
3.4.1. Task shifting of cervical cancer prevention using HIV care
While in sub-Saharan Africa nurses greatly outnumber doctors and
are often on the frontline in primary care services, their expanded role
in the post-HAART roll out era has been redeﬁned. The decentralization
process of HIV care launched in Kenya has considerably increased
services from 15 health facilities in 2003 to over 700 facilities by
December 2008 (National AIDS and STI control Programme, Ministry of
Health, 2009). A crucial aspect of this process has been the establish-
ment of HIV clinics at health centres and dispensaries, close to those in
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need, as well as the integration of HIV programs with other services
provided at the health facilities. Concurrently, the roll out of HAART
access to underserved communities gave impetus to a task shifting
approach in HIV care to deal with the severe shortage of health workers
in the front line.
Albeit poor access to services has resulted in the low cytological
screening coverage rates in Africa, new strategies facilitate screening in
resource-limited settings. Screening services have been expanding since
the WHO 2014 guideline advocating for a VIA or HPV-based “screen
and treat” approach, with mobile units reaching more rural areas and
cervical cancer prevention integrating HIV and family planning services
(Huchko et al., 2011). This approach contrasts with the previous
screening and diagnosis by the standard sequence of cytology, colpo-
scopy, biopsy, and histological conﬁrmation of CIN.
Building on previous successful public health initiatives, which in-
tegrated TB and antenatal care within HIV care, studies have shown
how the use of the HIV care infrastructure in sub-Saharan Africa has
been capitalised to integrate cervical cancer prevention in HIV-infected
women. In rural Mozambique, clinics were characterised by shortages
of human resources, equipment, poor paper record systems and a lim-
ited ability to follow-up with patients. These rural clinics managed to
piggyback on prior HIV infrastructure to implement chronic disease
screening and management for cervical screening (Moon et al., 2012).
In Zambia, a study demonstrated the feasibility of implementing a re-
ferral and management system for cryotherapy-ineligible women in a
“screen-and-treat” cervical cancer prevention program targeting HIV-
infected women (Pfaendler et al., 2008).
In Kenya, where there are only 40 registered and 81 enrolled nurses
per 100,000 people, outpatient treatment services, where cryotherapy
and loop electrosurgical excision procedure are performed, are largely
unavailable throughout the country (Ministry of Public Health and
Sanitation and Ministry of Medical Services, 2012). In a rural setting in
Western Kenya, a recent study showed that the established infra-
structure of an HIV treatment program was successfully used to build
capacity for cervical screening (Khozaim et al., 2014).Task-shifting and
population-based cervical screening was found to be feasible, never-
theless loss to follow-up and poor cytology infrastructure remained
important obstacles (Khozaim et al., 2014).
However, the availability of doctors in Kenya, which is 10 per
100,000 inhabitants (World Health Organization, 2017b), is even lower
than the availability of nurses and mostly concentrated in urban areas.
These barriers to cervical cancer prevention will undoubtedly hamper
the enhanced responsibility that nurses should be granted in cervical
cancer prevention in HIV-infected women within a high BV prevalence
setting. Suﬃcient and well trained human resources are necessary to
optimise investments made in diagnostic and treatment equipment and
infrastructure. In Sub Saharan Africa, diagnostic testing for STIs and BV
is often not available and most pregnant women are managed using
syndromic algorithms (Marx et al., 2010). However, a study in Kenya
reported poor detection of BV using syndromic diagnostic algorithms in
HIV-infected women by health care workers (Marx et al., 2010). This
underscores the need to enhance microscopy proﬁciency or Amsel
reading of BV in HIV-positive women, who possibly harbour several co-
infections. In addition, there is a need to develop nurses' skills in ap-
plying a management algorithm for BV associated cervicitis.
4. Discussion
Secondary prevention programs in Kenya will need to be tailored to
the local epidemiology of cervical dysplasia and ICC within the HIV-
infected Kenyan female population. In light of some shortcomings of
primary prevention for HIV-infected women in Kenya, risk factors for
pHR/HR HPV acquisition, including CD4 count, HAART use, FSW status
and BV presence may need to be considered when determining who
requires a more intense follow up. Furthermore, there may be risk
factors for abnormal cytology, including FSW status, multiple pHR/HR
HPV genotypes, which may require HIV-infected women to undergo
screening at more frequent intervals than the once every three years
WHO 2014 recommendation for HIV-infected women with negative
VIA and cytology tests. Until the advent of rapid, point of care and low-
cost HPV screening options, regular BV monitoring and its treatment
may also be sought to improve the speciﬁcity of VIA.
4.1. Strength and limitations
The studies used to draw our recommendations have the strength of
stemming from a wide array of settings, which enabled us to capture a
more representative HIV positive female population. However, our re-
commendations are subjected to the limitations of the cross-sectional
study design, which does not allow the fulﬁllment of the temporal
criterion for causality.
4.2. Generalizability
Our recommendations may be extrapolated to other clinical en-
vironments where women present similar levels of immunosuppression.
However, our recommendations may not be generalizable to HIV-in-
fected women who have scarce access to health care, as being of poorer
socio-economic status, they may be more at risk for co-infection of
poverty, including other STIs, TB, malaria, and helminthic infections.
These are infections, which may aﬀect persistence of certain pHR/HR
HPV genotypes and/or cervical dysplasia progression (Menon et al.,
2017a).
In order to determine a tailored screening interval, there are ﬁrst a
number of epidemiological, clinical and then programmatic research
gaps, which need to be addressed.
4.3. Research gaps
4.3.1. Research gaps for risk factors for pHR/HR HPV acquisition
Longitudinal studies should be undertaken to determine if treatment
of BV may reduce pHR/HR-HPV in genotype acquisition and/or cer-
vical dysplasia progression in HIV-infected women. Furthermore, the
epidemiology of BV recurrent BV within this population is still poorly
elucidated. A recent study on the epidemiology of BV in a cohort of
women at high risk for STI and HIV infection in Kampala, Uganda,
showed that of the HIV+ women who were treated for BV, 72% had a
second episode within 3 months (Francis et al., 2016).
Since the bivalent vaccine covers species α7 and α9, the burden of
HPV carcinogenesis in a fully vaccinated population might shift to the
potentially high-risk genotypes that are not currently covered by either
vaccine. Given the relatively high prevalence of HPV 53 as stand-alone
and in pairings in HIV-infected FSW with abnormal cytology, its po-
tential public health impact has yet to be estimated.
FSW are a major risk group for HPV, STIs and HIV. At the same time,
it is very diﬃcult to conduct methodologically-sound research for this
group due to the diﬃculties encountered in sampling methods and to
avoid exposing them to stigma and legal actions. It is therefore re-
commended that innovative methods to conduct epidemiological re-
search for FSW are explored, tested and validated.
If a causal relationship between treatment of BV and prevention of
HPV infection can be assumed, the population attributable fraction of
BV due to synergistic interactions with HIV and HPV should be esti-
mated. Although it has been shown that HAART use may reduce the
prevalence of various HPV genotypes, it is still unclear whether this
eﬀect is also valid for HPV16, which is, among all the genotypes, the
one with the highest potential to induce ICC. Due to the increasing
number of HIV-infected women accessing HAART at any CD4 count, it
is essential that this hypothesis is conﬁrmed.
4.3.2. Risk factors for abnormal cytology
Prospective studies need to be carried out to establish the
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relationship between BV and abnormal cytology within sub Saharan
HIV-infected women.
The high prevalence of concomitant STIs in HIV-infected women
warrant that their biological interactions and their subsequent capacity
to induce progression of cervical dysplasia be further explored.
Furthermore, the synergistic eﬀect of multiple pathogens implicated in
cervicitis must be elucidated.
While one of our studies in Kenya, (Menon et al. in press) has found
a propensity to cluster between phylogenetically similar α9 genotypes
in HIV-infected women with CIN 2+/HSIL, another study exhibited a
prominent role for non-alpha 9 and 7 genotypes, HPV 51 and 53
(Menon et al., 2017b). In order to target HIV-infected women har-
bouring more than one pHR/HR HPV genotype most at risk for pro-
gression, a large prospective study should be undertaken to investigate
clustering between phylogenetically similar or dissimilar phylogenetic
groups in HIV-infected women with CIN 2+/HSIL so that a less crude
triage than one based merely on the presence of more pHR/HR HPV
genotypes can be designed.
The screening of the pHR/HR-HPV genotypes 26, 53, 67, 70, 73 and
82 are currently not included in any HPV DNA screening protocols in
sub-Saharan Africa. The emergence of these serotypes will need to be
monitored as well as their synergistic/antagonistic interactions with
other HR-HPV genotypes. At the population level, aﬀordable point of
care nucleic acid ampliﬁcation methods to detect pHR HPV genotypes
are required throughout Kenya to explore how these genotypes will
behave in post-vaccination era. A personal level approach for secondary
prevention may be used if pHR HPV gentoypes as stand alone genotypes
are a risk factors for ICC.
4.3.3. Programmatic research gaps
Once there is a wider body of scientiﬁc evidence, there are a number
of programmatic research gaps which should be addressed.
In Kenya, a cluster randomised non-inferiority trial should be un-
dertaken in rural HIV management clinics to explore whether task
shifting to nurses of symptomatic management of BV and cervicitis in
HIV-HPV co-infected women is at least as eﬀective as when carried out
by physicians in secondary health care facilities. Moreover, a cost-
beneﬁt analysis should be undertaken to estimate whether bacterial
ecology monitoring by nurses in the front line may be a valuable
component of a primary cervical cancer prevention program.
Additionally, the population attribution fraction of STI due to sy-
nergistic interactions with BV, as well as their increased combined
cervical dysplasia genesis capacities, should be estimated. A cost-ben-
eﬁt analysis should be undertaken to assess whether there may be a
need to scale up STI prevention and management within the FSW po-
pulation, in addition to BV prevention within a cervical cancer pre-
vention framework.
As HIV self-testing has been found to be an acceptable method
among the general population and FSWs (Ochako et al., 2014), several
countries are beginning to introduce HIV self-testing as a promising
innovation to achieve faster scale up, prompting the WHO to develop
enabling guidelines (World Health Organization, 2016). A recent study
found that tampon-based self-collection for hrHPV mRNA, based on
molecular diagnostics aimed at detecting hrHPV viral integration, via
the production of oncogenic E6 and E7 messenger-RNA, in South Africa
could function as a viable method for cervical cancer screening among
HIV-infected women in low-resource settings (Adamson et al., 2015).
Provided the linkage between HIV and cervical cancer care in Kenya is
established, the acceptability and success of HIV self-testing may set the
stage for a concurrent roll out of HPV self-testing kits in this hard to
reach population, if it can be shown that there is an overall positive
public health impact.
5. Concluding remarks
The new WHO guideline to rescreen HIV infected women for HPV
within three years if tested negative by VIA or by cytological screening
may be more eﬀective if BV and its related cervicitis management be-
comes an integral component of primary and secondary prevention.
With earlier HAART initiation requiring regular immunological and
virological follow up, there are opportunities for a more regular cervical
screening provided that front line nurses are better equipped to deal
with challenges. The quadruple synergistic interaction between HIV,
HPV and BV and its related cervicitis may need to be reﬂected within a
larger prevention framework at the community level. The potential
synergistic interactions between BV, HIV, and HPV beg for an in-
tegrative cervical cancer prevention framework, with algorithms easy
to follow.
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